Prehospital Whole Blood Shows No Survival Edge Over Standard Components in Trauma
A landmark RCT of 616 trauma patients finds whole blood transfusion no better than red cells plus plasma at preventing death or massive transfusion.
Summary
The SWiFT trial, a phase 3 multicenter RCT across 10 UK air ambulance services, randomized 616 major trauma patients to receive either up to 2 units of whole blood or standard component therapy (red cells plus plasma) before hospital arrival. The primary composite outcome — death or massive transfusion within 24 hours — occurred in 48.7% of the whole-blood group versus 47.7% of standard-care patients, showing no statistically significant difference. Secondary outcomes including mortality at all timepoints and thrombotic events were also similar. Notably, prothrombin times were elevated more often in the whole-blood group. The findings challenge recent enthusiasm for whole blood in prehospital trauma care, suggesting standard component therapy remains an equivalent option.
Detailed Summary
Traumatic hemorrhage is a leading cause of preventable death globally, making optimal prehospital blood transfusion strategy a critical clinical question. Whole blood transfusion has resurged in popularity — particularly in military and trauma settings — based on observational data and physiological rationale suggesting it better restores hemostasis than separated components. However, robust randomized trial evidence has been lacking until now.
The SWiFT trial was a pragmatic, phase 3, multicenter, unblinded, randomized superiority trial conducted across 10 air ambulance services in England. Patients with major traumatic hemorrhage were assigned to receive up to 2 units of whole blood or up to 2 units each of red blood cells and plasma before hospital arrival. The primary composite endpoint was death from any cause or massive transfusion (≥10 units) within 24 hours of randomization.
Among 616 evaluable patients, the primary outcome occurred in 48.7% of whole-blood recipients versus 47.7% of standard-care recipients (RR 1.02; 95% CI 0.80–1.31; P=0.84). Mortality at all measured timepoints and rates of massive transfusion were comparable between groups. Serious adverse events were slightly more frequent in the standard-care group (37 vs. 31), and thrombotic event rates were similar. One notable signal was elevated prothrombin times in more whole-blood recipients (40.7% vs. 30.5%), raising questions about coagulation factor quality or balance in whole blood preparations.
For clinicians and trauma systems, these findings suggest that the logistical and cost investments required to maintain whole blood availability prehospital may not translate into measurable patient survival benefit over well-delivered component therapy. Standard care with red cells and plasma remains a fully supported approach.
Key caveats include the unblinded design, the restriction to 2-unit transfusion volumes which may not reflect higher-volume real-world scenarios, and the exclusion of traumatic cardiac arrest patients, limiting generalizability to the most critical cases.
Key Findings
- No significant difference in 24-hour death or massive transfusion: 48.7% (whole blood) vs. 47.7% (standard care).
- Mortality rates and massive transfusion incidence were similar at all measured timepoints across both groups.
- Prothrombin times were elevated in 40.7% of whole-blood vs. 30.5% of standard-care patients, a notable coagulation signal.
- Serious adverse events were slightly higher in the standard-care group (37 vs. 31); thrombotic events were comparable.
- Findings challenge the assumed superiority of prehospital whole blood over component therapy in civilian trauma.
Methodology
Phase 3, pragmatic, multicenter, unblinded, randomized superiority trial across 10 UK air ambulance services enrolling 942 patients (616 analyzed after exclusions). Patients were randomized to up to 2 units of whole blood or up to 2 units each of red cells and plasma prehospital. Primary composite endpoint was death or massive transfusion within 24 hours.
Study Limitations
The trial was unblinded, which may introduce bias in clinical decision-making post-randomization. The 2-unit cap on transfusion volume may not reflect higher-acuity scenarios where whole blood's theoretical advantages could be more pronounced. Exclusion of traumatic cardiac arrest patients limits applicability to the most severely injured trauma victims.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.